Comparison of the Minimum Inhibitory, Mutant Prevention and Minimum Bactericidal Concentrations of Ciprofloxacin, Levofloxacin and Garenoxacin Against Enteric Gram-negative Urinary Tract Infection Pathogens

References

• Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999; 29: 745–758.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Kellly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of E.coli from female outpatients in the United States. Antimicrob Agents Chemother 2002; 46: 2540–2545.
   PubMed Web of Science ®Google Scholar
• Gupta K, Hooton TM, Stamm WE. Increasing antimicro-bial resistance and the management of uncomplicated commu-nity-acquired urinary tract infections. Ann Intern Med 2001; 135: 41–50.
   PubMed Web of Science ®Google Scholar
• Hooton TM. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. Int J Antimicrob Agents 2003; 22: 65–72.
   PubMed Web of Science ®Google Scholar
• Nicolle LE. Urinary tract infection: Traditional pharma-cologic therapies. Am J Med 2002; 35s-44s.
   Google Scholar
• Blondeau JM. Gatifloxacin: a new fluoroquinolone. Expert Opin Investigat Drugs 2000; 9: 1877–1895.
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Gordon K, et al. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimi-crobial surveillance program (1998). J Antimicrob Chemother 2000; 45: 295–303.
   PubMed Web of Science ®Google Scholar
• Stamm WE. Scientific and clinical challenges in the management of urinary tract infections. Am J Med 2002; 113, sl-s4.
   Google Scholar
• Karlowsky JA, Thornsberry C, Jones ME, Sahm DF. Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin. Clin Infect Dis 2003; 36: 183–187.
   PubMed Web of Science ®Google Scholar
• Blondeau JM. A review of clinical trials with fluoro-quinolones with an emphasis on new agents. Expert Opin Investigat Drugs 2000; 9: 383–413.
   PubMed Web of Science ®Google Scholar
• Hooton TM. The current management strategies for community-acquired urinary tract infection. Infect Dis Clin North Am 2003; 17: 303–332.
   PubMed Web of Science ®Google Scholar
• Naber CK, Hammer M, Kinzig-Schippers M, et al. Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers. Antimicrob Agents Chemother 2001; 45, 3524–3530.
   PubMed Web of Science ®Google Scholar
• Naber KG, Sorgel F. Antibiotic therapy - rationale and evidence for optimal drug concentrations in prostate and sem-inal fluid and in prostatic tissue. Andrologia 2003; 35: 331–335.
   PubMed Web of Science ®Google Scholar
• Gilbert DN, Moellering Jr RC, Eliopoulos GM, Sande MA. The Sanford Guide to Antimicrobial Therapy 2004, 34th edn. Sperryville, VA: Antimicrobial Therapy Inc.
   Google Scholar
• Blondeau JM. Current issues in the management of uri-nary tract infections: extended release ciprofloxacin as a novel treatment option. Drugs 2004; 64: 611–628.
   PubMed Web of Science ®Google Scholar
• Felmingham D, Arakawa S. Resistance among urinary tract pathogens. Experience outside the USA. Clin Drug Investigat 2001; 21: 7–11.
   Web of Science ®Google Scholar
• Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003; 47: 3222–3332.
   PubMed Web of Science ®Google Scholar
• Christiansen KJ, Bell JM, Turnidge JD, Jones RN. Antimicrobial Activities of garenoxacin (BMS 283756) against Asia-Pacific region clinical isolates from the SENTRY Program, 1999 to 2001. Antimicrob Agents Chemother 2004; 48: 2049-2055.
   Google Scholar
• Fung-Tomc JC, Minassian B, Kolek B, et al. Antibacterial spectrum of a novel des-fluoro(6) quinolone, NMS-284756. Antimicrob Agents Chemother 2000; 44: 3351-3356.
   Google Scholar
• Blondeau JM, Yaschuk Y, Suter M, Vaughan D. In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study Group. J Antimicrob Chemother 1999; 43 Suppl A: 3-23.
   Google Scholar
• Murray PR, Baron EJ, Jorgenson J, Pfaller MA, Yolken RH. Manual of Clinical Microbiology. 8th Edition edn, ASM Press, Washington, DC., 2003: 1212.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacte-ria that grow aerobically (M7-A6). National Committee for Clinical Laboratory Standards, Wayne, PA., 2003.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement (M100-515), 2005.
   Google Scholar
• American Society for Microbiology. Part I: Minimum Bactericidal Concentration Testing. In: Clinical Microbiology Procedure Handbook . (Isenberg, H. D., Ed). American Society for Microbiology, 1992.
   Google Scholar
• Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical iso-lates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 433–438.
   PubMed Web of Science ®Google Scholar
• Hansen GT, Metzler K, Drlica K, Blondeau JM. Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47: 440–441.
   PubMed Web of Science ®Google Scholar
• Hansen G, Drlica K, Zhao X, Blondeau JM. The mutant prevention concentration (MPC) for ciprofloxacin (C) and levofloxacin (L) against non-urinary isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 2001; 47 (suppl 1): 37.
   Google Scholar
• Hansen G, Ekert L, Blondeau JM. Comparison of the minimum inhibitory concentration, mutant prevention concen-tration, and minimum bactericidal concentration of ciprofloxacin and levofloxacin against enteric gram-negative bacilli. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy), San Diego, Ca, USA. Sept 27-30, 2002.
   Google Scholar
• Gajjar DA, Bello A, Ge Z, Christopher L, Grasella M. Multiple dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother 2003; 47: 2256–2263.
   PubMed Web of Science ®Google Scholar
• Morrissey I, George JT. Measurement of the bacterici-dal activity of fluoroquinolones against Streptococcus pneu-moniae using the bactericidal index method. Intern J Antimicrob Agents 2001; 17: 33–37.
   PubMed Web of Science ®Google Scholar
• Noskin GA, Mehl P, Warren JR. Bactericidal activity of the fluoroquinolone WIN 57273 against high-level gentamicin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1993; 37: 2470–2473.
   PubMed Web of Science ®Google Scholar
• Visser MR, Rozenberg-Arska M, Beumer H, Hoepelman IM, Verhoef J. Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone. Antimicrob Agents Chemother 1991; 35: 858–868.
   PubMed Web of Science ®Google Scholar
• Marcusson LL, Olofsson SK, Komp Lindgren P, Cars O, Hughes D. Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coll. J Antimicrob Chemother 2005; 55: 938–943.
   PubMed Web of Science ®Google Scholar
• Blondeau JM, Hansen G, Metzler KL, Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother 2004; 16 (suppl n. 3): 1-19.
   Google Scholar
• Brittain DC, Scully BE, McElrath MJ, Steinman R, Labthavikul P, Neu H. The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. J Clin Pharmacol 1985; 25, 82–88.
   PubMed Web of Science ®Google Scholar
• Naber KG. Which fluroqouinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 2001; 17: 331–342.
   PubMed Web of Science ®Google Scholar
• Felmingham DAS. Resistance among urinary tract pathogens. Expereinece outside the USA. Clin Drug Investigat 2001; 21: 7–11.
   Web of Science ®Google Scholar
• Karlowsky JA, Jones ME, Thornsberry C, Critchley I, Kelly LJ, Sahm DF. Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpa-tients across the US in 1999. Int J Antimicrob Agents 2001; 18: 121–127.
   PubMed Web of Science ®Google Scholar
• Masterton RG, Bochsler JA. High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. J Antimicrob Chemother 1995; 35: 129–137.
   PubMed Web of Science ®Google Scholar
• McCart, JM, Richard G, Huck W, et al. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimetho-prim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group. Am J Med 1999; 106: 292–299.
   Google Scholar
• Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geo-graphical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002; 34: 1165–1169.
   Google Scholar
• Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephri-tis in women: a randomized trial. JAMA 2000; 283: 1583-1590.
   Google Scholar
• Wright SW, Wrenn KD, Haynes ML. Trimethoprim-sul-famethoxazole resistance among urinary coliform isolates. J Genitourinary Med 1999; 14: 606–609.
   Web of Science ®Google Scholar
• Sheng W-H, Chen Y-C, Wang JT, Chang SC, Luh KT, Hsieh WC. Emerging fluoroquinolone-resistance for common clinically important gram-negative bacteria in Taiwan. Diagn Microbiol Infect Dis 2002; 43: 141–147.
   PubMed Web of Science ®Google Scholar
• Marians KJ, Hiasa H. Mechanism of quinolone action. A drug-induced structural perturbation of the DNA precedes strand cleavage by topoisomerase IV. J Biol Chem 1997; 272: 9401–9409.
   Google Scholar